Company Profile For SkyePharma PLC

SkyePharma PLC, together with its subsidiaries, is a specialty pharmaceutical group, which uses its multiple drug delivery technologies to create a product pipeline for out-licensing to marketing partners. The Company is engaged in the research, development, manufacture and sale of prescription pharmaceutical products. The Company's product line includes Flutiform HFA-MDI, Pulmicort HFA-MDI, Foradil Certihaler, Paxil CR, Xatral OD, Solaraze, Triglide(fenofibrate), Requip Once-a-day, ZYFLO CR, Sular, Lodotra and SKP-1041.

BRIEF: For the six months ended 30 June 2009, SkyePharma PLC's revenue decreased 10% to £25.5M. Net loss from continuing operation decreased 10% to £26.7M. Revenues reflect an decrease in Royalty income, lower Licence Signing & Milestone fees and Manufacturing & Distribution income. Lower net loss reflects an increase in selling, marketing & distribution expenses, the presence of other expense and an increase in finance costs.